BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 37909987)

  • 21. Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer.
    Guibert N; Hu Y; Feeney N; Kuang Y; Plagnol V; Jones G; Howarth K; Beeler JF; Paweletz CP; Oxnard GR
    Ann Oncol; 2018 Apr; 29(4):1049-1055. PubMed ID: 29325035
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single-cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib-resistant patients.
    Chen J; Facchinetti F; Braye F; Yurchenko AA; Bigot L; Ponce S; Planchard D; Gazzah A; Nikolaev S; Michiels S; Vasseur D; Lacroix L; Tselikas L; Nobre C; Olaussen KA; Andre F; Scoazec JY; Barlesi F; Soria JC; Loriot Y; Besse B; Friboulet L
    Ann Oncol; 2022 Apr; 33(4):434-444. PubMed ID: 35066105
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence, clinical and molecular characteristics of early stage EGFR-mutated lung cancer in a real-life West-European cohort: Implications for adjuvant therapy.
    Hondelink LM; Ernst SM; Atmodimedjo P; Cohen D; Wolf JL; Dingemans AC; Dubbink HJ; von der Thüsen JH
    Eur J Cancer; 2023 Mar; 181():53-61. PubMed ID: 36638752
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genomic Landscape of Primary Resistance to Osimertinib Among Hispanic Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): Results of an Observational Longitudinal Cohort Study.
    Chamorro DF; Cardona AF; Rodríguez J; Ruiz-Patiño A; Arrieta O; Moreno-Pérez DA; Rojas L; Zatarain-Barrón ZL; Ardila DV; Viola L; Recondo G; Blaquier JB; Martín C; Raez L; Samtani S; Ordóñez-Reyes C; Garcia-Robledo JE; Corrales L; Sotelo C; Ricaurte L; Cuello M; Mejía S; Jaller E; Vargas C; Carranza H; Otero J; Archila P; Bermudez M; Gamez T; Russo A; Malapelle U; de Miguel Perez D; de Lima VCC; Freitas H; Saldahna E; Rolfo C; Rosell R;
    Target Oncol; 2023 May; 18(3):425-440. PubMed ID: 37017806
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Liquid Biopsy Testing for the Management of Patient with Non-Small Cell Lung Cancer Carrying a Rare Exon-20 EGFR Insertion.
    Morabito A; Manzo A; Montanino A; Rachiglio AM; Sforza V; Pasquale R; Costanzo R; Maiello MR; Sandomenico C; Gallo M; Palumbo G; De Luca A; La Rocca A; Martucci N; De Cecio R; Picone C; Lastoria S; Normanno N
    Oncologist; 2022 Feb; 27(1):7-12. PubMed ID: 35305107
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation.
    Li C; Nie W; Guo J; Xiong A; Zhong H; Chu T; Zhong R; Xu J; Lu J; Zheng X; Zhang B; Shen Y; Pan F; Han B; Zhang X
    Respir Res; 2021 May; 22(1):145. PubMed ID: 33975616
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Challenging BRAF/EGFR co-inhibition in NSCLC using sequential liquid biopsies.
    Solassol J; Vendrell JA; Senal R; Audran P; Leenhardt F; Quantin X
    Lung Cancer; 2019 Jul; 133():45-47. PubMed ID: 31200827
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients.
    Yang Z; Yang N; Ou Q; Xiang Y; Jiang T; Wu X; Bao H; Tong X; Wang X; Shao YW; Liu Y; Wang Y; Zhou C
    Clin Cancer Res; 2018 Jul; 24(13):3097-3107. PubMed ID: 29506987
    [No Abstract]   [Full Text] [Related]  

  • 29. Acquired EGFR C797G Mutation Detected by Liquid Biopsy as Resistance Mechanism After Treatment With Osimertinib: A Case Report.
    DE Carlo E; Schiappacassi M; Pelizzari G; Baresic T; Del Conte A; Stanzione B; DA Ros V; Doliana R; Baldassarre G; Bearz A
    In Vivo; 2021; 35(5):2941-2945. PubMed ID: 34410991
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Next-Generation Sequencing Liquid Biopsy-Guided Osimertinib Rechallenge in EGFR-Mutated Advanced Non-Small-Cell Lung Cancer Patients.
    Fuchs V; Kian W; Lichtenberg R; Cooper JM; Remilah AA; Levin D; Peled N; Roisman LC
    Clin Drug Investig; 2022 Feb; 42(2):185-192. PubMed ID: 35044639
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer.
    van Veggel B; Madeira R Santos JFV; Hashemi SMS; Paats MS; Monkhorst K; Heideman DAM; Groves M; Radonic T; Smit EF; Schuuring E; van der Wekken AJ; de Langen AJ
    Lung Cancer; 2020 Mar; 141():9-13. PubMed ID: 31926441
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histomolecular Resistance Mechanisms to First-Line Osimertinib in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multicentric Retrospective French Study.
    Akli A; Girard N; Fallet V; Rousseau-Bussac G; Gounant V; Friard S; Trédaniel J; Dujon C; Wislez M; Duchemann B; Giroux-Leprieur E
    Target Oncol; 2022 Nov; 17(6):675-682. PubMed ID: 36129569
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Novel Acquired Exon 20 EGFR M766Q Mutation in Lung Adenocarcinoma Mediates Osimertinib Resistance but is Sensitive to Neratinib and Poziotinib.
    Castellano GM; Aisner J; Burley SK; Vallat B; Yu HA; Pine SR; Ganesan S
    J Thorac Oncol; 2019 Nov; 14(11):1982-1988. PubMed ID: 31254668
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes.
    Mu Y; Hao X; Xing P; Hu X; Wang Y; Li T; Zhang J; Xu Z; Li J
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2427-2433. PubMed ID: 32385709
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monitoring epidermal growth factor receptor C797S mutation in Japanese non-small cell lung cancer patients with serial cell-free DNA evaluation using digital droplet PCR.
    Ariyasu R; Uchibori K; Sasaki T; Tsukahara M; Kiyotani K; Yoshida R; Ono Y; Kitazono S; Ninomiya H; Ishikawa Y; Mizukami Y; Yanagitani N; Fujita N; Nishio M; Katayama R
    Cancer Sci; 2021 Jun; 112(6):2371-2380. PubMed ID: 33686722
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Late recurrence of lung adenocarcinoma harboring EGFR exon 20 insertion (A763_Y764insFQEA) mutation successfully treated with osimertinib.
    Kunimasa K; Nishino K; Kukita Y; Matsumoto S; Kawachi H; Kawamura T; Inoue T; Tamiya M; Honma K; Sugimoto N; Yamasaki T; Imamura F; Goto K; Kumagai T
    Cancer Genet; 2021 Aug; 256-257():57-61. PubMed ID: 33901930
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison between Three Different Techniques for the Detection of EGFR Mutations in Liquid Biopsies of Patients with Advanced Stage Lung Adenocarcinoma.
    Casula M; Pisano M; Paliogiannis P; Colombino M; Sini MC; Zinellu A; Santeufemia D; Manca A; Casula S; Tore S; Lobrano R; Sardinian Lung Cancer Study Group ; Cossu A; Palmieri G
    Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047382
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of comprehensive analysis with circulating tumor DNA in advanced non-small cell lung cancer patients considered for osimertinib treatment.
    Sueoka-Aragane N; Nakashima C; Yoshida H; Matsumoto N; Iwanaga K; Ebi N; Nishiyama A; Yatera K; Kuyama S; Fukuda M; Ushijima S; Umeguchi H; Harada D; Kashiwabara K; Suetsugu T; Fujimoto N; Tanaka F; Uramoto H; Yoshii C; Nakatomi K; Koh G; Seki N; Aoe K; Nosaki K; Inoue K; Takamori A; Kawaguchi A
    Cancer Med; 2021 Jun; 10(12):3873-3885. PubMed ID: 33982444
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cell-Free Circulating Tumour DNA Blood Testing to Detect
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2020; 20(5):1-176. PubMed ID: 32206157
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current treatment strategies for EGFR-mutated non-small cell lung cancer: from first line to beyond osimertinib resistance.
    Araki T; Kanda S; Horinouchi H; Ohe Y
    Jpn J Clin Oncol; 2023 Jun; 53(7):547-561. PubMed ID: 37279591
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.